全文获取类型
收费全文 | 3580篇 |
免费 | 184篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 52篇 |
妇产科学 | 84篇 |
基础医学 | 424篇 |
口腔科学 | 102篇 |
临床医学 | 271篇 |
内科学 | 807篇 |
皮肤病学 | 110篇 |
神经病学 | 562篇 |
特种医学 | 117篇 |
外科学 | 599篇 |
综合类 | 9篇 |
预防医学 | 127篇 |
眼科学 | 32篇 |
药学 | 190篇 |
中国医学 | 3篇 |
肿瘤学 | 283篇 |
出版年
2024年 | 6篇 |
2023年 | 27篇 |
2022年 | 81篇 |
2021年 | 141篇 |
2020年 | 83篇 |
2019年 | 85篇 |
2018年 | 125篇 |
2017年 | 108篇 |
2016年 | 122篇 |
2015年 | 113篇 |
2014年 | 174篇 |
2013年 | 212篇 |
2012年 | 293篇 |
2011年 | 296篇 |
2010年 | 178篇 |
2009年 | 149篇 |
2008年 | 276篇 |
2007年 | 229篇 |
2006年 | 190篇 |
2005年 | 197篇 |
2004年 | 188篇 |
2003年 | 185篇 |
2002年 | 119篇 |
2001年 | 30篇 |
2000年 | 26篇 |
1999年 | 37篇 |
1998年 | 16篇 |
1997年 | 9篇 |
1996年 | 11篇 |
1995年 | 9篇 |
1994年 | 2篇 |
1993年 | 5篇 |
1992年 | 5篇 |
1991年 | 9篇 |
1990年 | 10篇 |
1989年 | 12篇 |
1988年 | 11篇 |
1987年 | 8篇 |
1986年 | 3篇 |
1985年 | 4篇 |
1979年 | 1篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1972年 | 1篇 |
1970年 | 1篇 |
1969年 | 3篇 |
1966年 | 1篇 |
排序方式: 共有3793条查询结果,搜索用时 15 毫秒
61.
Giuseppe G L Biondi-Zoccai Marzia Lotrionte Pierfrancesco Agostoni Antonio Abbate Massimiliano Fusaro Francesco Burzotta Luca Testa Imad Sheiban Giuseppe Sangiorgi 《European heart journal》2006,27(22):2667-2674
AIMS: The role of aspirin in patients with coronary artery disease (CAD) is well established, yet patients happen to discontinue aspirin according to physician's advice or unsupervised. We thus undertook a systematic review to appraise the hazards inherent to aspirin withdrawal or non-compliance in subjects at risk for or with CAD. METHODS AND RESULTS: Electronic databases were systematically searched (updated January 2006). Study designs, patient characteristics, and outcomes were abstracted. Pooled estimates for odds ratios (OR) were computed according to random-effect methods. From the 612 screened studies, six were selected (50,279 patients). One study (31,750 patients) focused on adherence to aspirin therapy in the secondary prevention of CAD, two studies (2594) on aspirin discontinuation in acute CAD, two studies (13,706) on adherence to aspirin therapy before or shortly after coronary artery bypass grafting, and another (2229) on aspirin discontinuation among patients undergoing drug-eluting stenting. Overall, aspirin non-adherence/withdrawal was associated with three-fold higher risk of major adverse cardiac events (OR=3.14 [1.75-5.61], P=0.0001). This risk was magnified in patients with intracoronary stents, as discontinuation of antiplatelet treatment was associated with an even higher risk of adverse events (OR=89.78 [29.90-269.60]). CONCLUSION: Non-compliance or withdrawal of aspirin treatment has ominous prognostic implication in subjects with or at moderate-to-high risk for CAD. Aspirin discontinuation in such patients should be advocated only when bleeding risk clearly overwhelms that of atherothrombotic events. 相似文献
62.
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study 总被引:27,自引:0,他引:27
Brunetto MR Oliveri F Coco B Leandro G Colombatto P Gorin JM Bonino F 《Journal of hepatology》2002,36(2):263-270
BACKGROUND/AIMS: We studied the influence of biochemical and virologic patterns and interferon on the outcome of anti-HBe positive chronic hepatitis B in 164 (103 treated) consecutive patients, followed-up prospectively for a mean of 6 years (21 months-12 years). METHODS: Histology, biochemical and virologic profiles were characterized by monthly monitoring during the first 12 months of follow-up. Thereafter patients underwent blood and clinical controls every 4 and 6 months, respectively. Cirrhosis at follow-up histology or end stage complications of cirrhosis served as end points for the analysis of factors influencing disease progression in patients with baseline chronic hepatitis or cirrhosis, respectively. RESULTS: Disease progression was associated with older age (P<0.001), absence of previous HBeAg history (P=0.017) and higher serum HBV-DNA levels (P=0.009) (more frequently observed in unremitting disease profile, P=0.012) at multivariate analysis. Fluctuations of IgM anti-HBc levels (associated with disease exacerbations, P=0.045) correlated with end stage complications in cirrhotics (P=0.011). Disease improved in 14.6 and 1.6% of treated and untreated patients, respectively (P=0.015): interferon slowed disease progression (P<0.001). CONCLUSIONS: The outcome of anti-HBe positive chronic hepatitis B is worsened by older age and persistent viral replication or hepatitis exacerbations in chronic hepatitis or in cirrhotic patients, respectively. Interferon reduces by 2.5-folds disease progression. 相似文献
63.
Lauren G. Kanapka R. Paul Wadwa Marc D. Breton Katrina J. Ruedy Laya Ekhlaspour Gregory P. Forlenza Eda Cengiz Melissa J. Schoelwer Emily Jost Lori Carria Emma Emory Liana J. Hsu Stuart A. Weinzimer Mark D. DeBoer Bruce A. Buckingham Mary Oliveri Craig Kollman Betsy B. Dokken Daniel Cheravvsky Roy W. Beck 《Diabetes care》2021,44(2):473
OBJECTIVETo further evaluate the safety and efficacy of the Control-IQ closed-loop control (CLC) system in children with type 1 diabetes.RESEARCH DESIGN AND METHODSAfter a 16-week randomized clinical trial (RCT) comparing CLC with sensor-augmented pump (SAP) therapy in 101 children 6–13 years old with type 1 diabetes, 22 participants in the SAP group initiated use of the CLC system (referred to as SAP-CLC cohort), and 78 participants in the CLC group continued use of CLC (CLC-CLC cohort) for 12 weeks.RESULTSIn the SAP-CLC cohort, mean percentage of time in range 70–180 mg/dL (TIR) increased from 55 ± 13% using SAP during the RCT to 65 ± 10% using CLC (P < 0.001), with 36% of the cohort achieving TIR >70% plus time <54 mg/dL <1% compared with 14% when using SAP (P = 0.03). Substantial improvement in TIR was seen after the 1st day of CLC. Time <70 mg/dL decreased from 1.80% to 1.34% (P < 0.001). In the CLC-CLC cohort, mean TIR increased from 53 ± 17% prerandomization to 67 ± 10% during the RCT and remained reasonably stable at 66 ± 10% through the 12 weeks post-RCT. No episodes of diabetic ketoacidosis or severe hypoglycemia occurred in either cohort.CONCLUSIONSThis further evaluation of the Control-IQ CLC system supports the findings of the preceding RCT that use of a closed-loop system can safely improve glycemic control in children 6–13 years old with type 1 diabetes from the 1st day of use and demonstrates that these improvements can be sustained through 28 weeks of use. 相似文献
64.
Lethal cancer and chronic untreatable viral disease with life threatening consequences are among the major burden for morbidity and mortality in the western world. A large number of resources are employed every year in identification of new drugs to treat this condition. A remarkable percentage of resources are wasted for safety concerns about possible acute cardiac or pulmonary toxicity of the new identified compounds, that are rejected without further development even when promising. ExtraCorporeal Membrane Oxygenation (ECMO) is an established technique to support and replace cardio-pulmonary function that underwent rapid technologic improvement in the last years, resulting in reduced complication rate. ECMO has been used with success to treat acute life-threatening cardiac and pulmonary toxicity. Our hypothesis is that the new ECMO technological improvement could make this technique available to other setting, such as lethal cancer and infectious diseases, where it can provide a safe base to overwhelm acute cardiac and pulmonary toxicity of chemotoxic drugs and techniques. New drugs and old promising compounds rejected for toxicity could thus be re-introduced and employed, opening a new scenario in the treatment of life-threatening diseases. 相似文献
65.
Bucello Sebastiano Annovazzi Pietro Ragonese Paolo Altieri Marta Barcella Valeria Bergamaschi Roberto Bianchi Alessia Borriello Giovanna Buscarinu Maria Chiara Callari Graziella Capobianco Marco Capone Fioravante Cavalla Paola Cavarretta Rosella Cortese Antonio De Luca Giovanna Di Filippo Massimiliano Dattola Vincenzo Fantozzi Roberta Ferraro Elisabetta Filippi Maria Maddalena Gasperini Claudio Grimaldi Luigi Maria Edoardo Landi Doriana Re Marianna Lo Mallucci Giulia Manganotti Paolo Marfia Girolama Alessandra Mirabella Massimiliano Perini Paola Pisa Marco Realmuto Sabrina Russo Margherita Tomassini Valentina Torri-Clerici Valentina Liliana Adriana Zaffaroni Mauro Zuliani Cristina Zywicki Sofia Filippi Massimo Prosperini Luca 《Journal of neurology》2021,268(8):2922-2932
Journal of Neurology - To identify baseline factors associated with disease activity in patients with relapsing–remitting multiple sclerosis (RRMS) under teriflunomide treatment. This was an... 相似文献
66.
67.
Christian Carulli Fabrizio Matassi Roberto Civinini Massimo Morfini Massimiliano Tani Massimo Innocenti 《The Knee》2013,20(1):36-39
IntroductionHaemophilic arthropathy is the most common clinical manifestation of haemophilia, secondary to recurrent haemarthrosis and chronic synovitis, and the knee represents the main target joint. Modern bleeding prevention has significatively limited the incidence of severe arthropathy, and primary approach is usually conservative. Viscosupplementation is felt as one of the most efficient treatments for the early stages of knee haemophilic arthropathy, based on short-term follow-up studies. The aim of this prospective case series study is to assess the clinical effectiveness of intra-articular administration of hyaluronic acid in the knee, evaluating long-term results, and focusing on the necessity of further treatments after viscosupplementation.MethodsTwenty-seven haemophilic patients with knee arthropathy underwent at least two cycles of injections of hyaluronians between 2003 and 2009. They were evaluated with VAS, SF-36, WFH, Pettersson score, and WOMAC, with a seven-year follow-up.ResultsAll patients showed improvement in pain relief and functional recovery without any complications. Considering the severity of arthropathy in haemophilic patients, only a limited number of subjects (five) underwent total knee arthroplasty for persistent pain or functional limitation.ConclusionsViscosupplementation is a safe and effective therapeutic strategy in knee haemophilic arthropathy, with no complications, persisting good clinical results, and determining in most cases a delay of surgery. 相似文献
68.
69.